FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2068049003> ?p ?o ?g. }

• W2068049003 endingPage "564" @default.
• W2068049003 startingPage "558" @default.
• W2068049003 abstract "Anti-IgE (omalizumab) inhibited early and late asthmatic reactions and infiltration of inflammatory cells in asthmatic bronchial biopsies at baseline. The effect of chronic allergen exposure on these outcomes is unknown. Repeat allergen challenge in human skin represents a suitable model to address this question.To study the effect of anti-IgE (omalizumab) on early-phase (EPR) and late-phase (LPR) skin reactions and cellular infiltration by using a repeat skin allergen challenge designed to imitate chronic allergen exposure.Twenty-four atopic allergic volunteers received omalizumab or placebo for 12 weeks. Paired intradermal challenges of allergen (30 biological units) and diluent control were administered on 9 occasions at 2-week intervals. Early-phase and late-phase skin reactions and cellular infiltration in skin biopsies (using immunohistochemistry and in situ hybridization) were measured at intervals.Compared with placebo, omalizumab-treated patients had a progressive reduction in the LPR that was significantly greater than its effect on the EPR (median, --63% vs--24% respectively; P=.009). In addition, significant reduction of the LPR was reached within 2 weeks of commencing treatment, compared with 8 weeks for the EPR. There was a priming effect of repeated allergen challenge on infiltration of eosinophil, neutrophil, T(H)2 (CD3(+)/IL-4(+)), and total FcepsilonRI(+) cells in patients on placebo that was abrogated in those receiving omalizumab.The more marked effect of omalizumab on the LPR and prevention of the repeat-dose priming effect on several inflammatory cell types support a role for anti-IgE treatment in conditions associated with chronic allergic inflammation." @default.
• W2068049003 created "2016-06-24" @default.
• W2068049003 creator A5004428649 @default.
• W2068049003 creator A5022388448 @default.
• W2068049003 creator A5022389916 @default.
• W2068049003 creator A5023307885 @default.
• W2068049003 creator A5064327491 @default.
• W2068049003 creator A5077546670 @default.
• W2068049003 creator A5086889813 @default.
• W2068049003 date "2005-09-01" @default.
• W2068049003 modified "2023-09-22" @default.
• W2068049003 title "Anti-IgE (omalizumab) inhibits late-phase reactions and inflammatory cells after repeat skin allergen challenge" @default.
• W2068049003 cites W1522506802 @default.
• W2068049003 cites W180810881 @default.
• W2068049003 cites W1910182345 @default.
• W2068049003 cites W1969132883 @default.
• W2068049003 cites W1970648068 @default.
• W2068049003 cites W2009608314 @default.
• W2068049003 cites W2026119244 @default.
• W2068049003 cites W2032260549 @default.
• W2068049003 cites W2035845602 @default.
• W2068049003 cites W2047251211 @default.
• W2068049003 cites W2055705628 @default.
• W2068049003 cites W2065071227 @default.
• W2068049003 cites W2069243125 @default.
• W2068049003 cites W2084399363 @default.
• W2068049003 cites W2089367605 @default.
• W2068049003 cites W2092368654 @default.
• W2068049003 cites W2096018298 @default.
• W2068049003 cites W2098968578 @default.
• W2068049003 cites W2100985076 @default.
• W2068049003 cites W2101375237 @default.
• W2068049003 cites W2104449005 @default.
• W2068049003 cites W2110052844 @default.
• W2068049003 cites W2116313488 @default.
• W2068049003 cites W2118774861 @default.
• W2068049003 cites W2136060598 @default.
• W2068049003 cites W2160953471 @default.
• W2068049003 cites W2166685437 @default.
• W2068049003 doi "https://doi.org/10.1016/j.jaci.2005.05.035" @default.
• W2068049003 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/16159624" @default.
• W2068049003 hasPublicationYear "2005" @default.
• W2068049003 type Work @default.
• W2068049003 sameAs 2068049003 @default.
• W2068049003 citedByCount "90" @default.
• W2068049003 countsByYear W20680490032012 @default.
• W2068049003 countsByYear W20680490032013 @default.
• W2068049003 countsByYear W20680490032014 @default.
• W2068049003 countsByYear W20680490032015 @default.
• W2068049003 countsByYear W20680490032016 @default.
• W2068049003 countsByYear W20680490032017 @default.
• W2068049003 countsByYear W20680490032018 @default.
• W2068049003 countsByYear W20680490032019 @default.
• W2068049003 countsByYear W20680490032020 @default.
• W2068049003 countsByYear W20680490032022 @default.
• W2068049003 countsByYear W20680490032023 @default.
• W2068049003 crossrefType "journal-article" @default.
• W2068049003 hasAuthorship W2068049003A5004428649 @default.
• W2068049003 hasAuthorship W2068049003A5022388448 @default.
• W2068049003 hasAuthorship W2068049003A5022389916 @default.
• W2068049003 hasAuthorship W2068049003A5023307885 @default.
• W2068049003 hasAuthorship W2068049003A5064327491 @default.
• W2068049003 hasAuthorship W2068049003A5077546670 @default.
• W2068049003 hasAuthorship W2068049003A5086889813 @default.
• W2068049003 hasConcept C141105273 @default.
• W2068049003 hasConcept C142724271 @default.
• W2068049003 hasConcept C159654299 @default.
• W2068049003 hasConcept C203014093 @default.
• W2068049003 hasConcept C204787440 @default.
• W2068049003 hasConcept C207480886 @default.
• W2068049003 hasConcept C27081682 @default.
• W2068049003 hasConcept C2776042228 @default.
• W2068049003 hasConcept C2777037409 @default.
• W2068049003 hasConcept C2778564945 @default.
• W2068049003 hasConcept C2780510475 @default.
• W2068049003 hasConcept C71924100 @default.
• W2068049003 hasConceptScore W2068049003C141105273 @default.
• W2068049003 hasConceptScore W2068049003C142724271 @default.
• W2068049003 hasConceptScore W2068049003C159654299 @default.
• W2068049003 hasConceptScore W2068049003C203014093 @default.
• W2068049003 hasConceptScore W2068049003C204787440 @default.
• W2068049003 hasConceptScore W2068049003C207480886 @default.
• W2068049003 hasConceptScore W2068049003C27081682 @default.
• W2068049003 hasConceptScore W2068049003C2776042228 @default.
• W2068049003 hasConceptScore W2068049003C2777037409 @default.
• W2068049003 hasConceptScore W2068049003C2778564945 @default.
• W2068049003 hasConceptScore W2068049003C2780510475 @default.
• W2068049003 hasConceptScore W2068049003C71924100 @default.
• W2068049003 hasIssue "3" @default.
• W2068049003 hasLocation W20680490031 @default.
• W2068049003 hasLocation W20680490032 @default.
• W2068049003 hasOpenAccess W2068049003 @default.
• W2068049003 hasPrimaryLocation W20680490031 @default.
• W2068049003 hasRelatedWork W2014471812 @default.
• W2068049003 hasRelatedWork W2083087446 @default.
• W2068049003 hasRelatedWork W2129149137 @default.
• W2068049003 hasRelatedWork W2145013427 @default.
• W2068049003 hasRelatedWork W2170347784 @default.

• next